Join Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.
Advertisement
————————————
Panelists
Ahmed Obeidat, MD, PhD Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin
Hesham Abboud, MD, PhD Assistant Professor of Neurology, Case Western Reserve University School of Medicine; Director, Multiple Sclerosis and Neuroimmunology Program, Staff Neurologist, Parkinson’s and Movement Disorders Center, University Hospitals, Cleveland Medical Center
Rana K. Zabad, MD, FAAN Professor, Department of Neurological Sciences, Chief, Multiple Sclerosis/Neuroimmunology Section, Program Director, Multiple Sclerosis Fellowship, University of Nebraska Medical Center
Key Learning Objectives
Virtual patient visits during COVID-19 when diagnosing MS
Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.